Rare "Black Bone Disease" Gets Its First Approved Treatment

For people with alkaptonuria, a rare inherited metabolic disorder sometimes called "black bone disease," there had never been an approved medicine — only management of the pain and joint damage it causes. That changed on 11 June 2025, when the US Food and Drug Administration approved nitisinone as the first and only treatment for adults with the condition.

Alkaptonuria affects roughly one in 100,000 to 250,000 people worldwide. Those who have it cannot fully break down an amino acid byproduct called homogentisic acid (HGA), which accumulates over years and slowly turns cartilage and bone dark and brittle, leading to severe arthritis, chronic pain and other complications. Nitisinone blocks the enzyme that produces HGA, and in studies it reduced urinary excretion of the acid by 95 percent on average. A three-year randomized clinical trial of 40 patients, supported by the US National Institutes of Health, found that nitisinone improved pain, energy levels and physical functioning compared with untreated controls.

The approval matters beyond the small number of patients it directly serves. Rare diseases are often overlooked because markets are tiny, so a dedicated, evidence-backed therapy for a condition this uncommon signals that even very rare disorders can attract serious drug development.

Sensible caveats apply. Nitisinone manages alkaptonuria; it does not cure the underlying genetic defect, and because it works by shifting how the body processes the amino acid tyrosine, patients typically need dietary monitoring and follow-up care. The clinical trial that supported approval was relatively small, as is common for ultra-rare conditions. Even so, after generations in which alkaptonuria patients had no targeted option at all, the arrival of a first approved treatment is a quietly significant win for the rare-disease community.